Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 85% confidence The document is a U.S. SEC Form 6-K “Current Report of Foreign Private Issuer” filed under the Exchange Act. It does not contain substantive financial statements or management discussion, but merely furnishes a press release as Exhibit 99.1. Under the classification rules, SEC Form 6-K filings are treated as general regulatory announcements (fallback category) rather than as a standalone report like an annual or interim financial report. Therefore, the correct classification is Regulatory Filings (RNS).
2026-06-03 English
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
Regulatory Filings Classification · 15% confidence The document is a corporate press release announcing the presentation of clinical trial data at a scientific conference (EULAR 2026). It does not contain financial results, management discussion of financial performance, regulatory form references, or actual report content. It is not an earnings release, investor presentation, or any focused financial or governance filing. It also does not announce the publication of a report. Therefore, it does not fit any specific category except the general fallback for miscellaneous announcements: “Regulatory Filings” (RNS).
2026-06-03 English
argenx to Host Myositis R&D Webinar on June 23, 2026
Investor Presentation Classification · 72% confidence The document is a corporate announcement inviting investors to attend a webinar (‘R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis’) detailing the company’s research and development strategy. It is clearly an investor‐oriented presentation event rather than a regulatory filing, financial report, or earnings release. Therefore, it best fits the Investor Presentation category.
2026-05-28 English
argenx to Present at Upcoming Investor Conferences
Investor Presentation Classification · 60% confidence The document is a corporate press release announcing that argenx’s management team will participate in upcoming investor conferences, including dates, venues, and webcast details. It does not contain financial results or regulatory filings, nor does it report on dividends, voting, or legal matters. This is an announcement of investor presentations/conference events, which falls under the Investor Presentation category.
2026-05-27 English
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing FDA approval of a product label expansion. It contains no financial statements or investor call transcript, nor is it a formal regulatory submission or detailed report. It is an external announcement of approval (“inside information” under EU MAR) and does not fit other categories (e.g., earnings release, capital update, proxy statement). This aligns with the fallback “Regulatory Filings” category for miscellaneous regulatory announcements (RNS).
2026-05-11 English
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement of the first quarter 2026 financial results of argenx, including comprehensive financial data such as product net sales, operating income, expenses, profit, and earnings per share. It also provides a business update, pipeline progress, management changes, and future financial calendar dates. The presence of unaudited condensed consolidated interim financial statements and substantive financial analysis for a quarter indicates this is a quarterly financial report. The document is lengthy (15,000 characters) and contains actual financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.